Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
Active, not recruiting · NCT05874635 · Registry updated 2025-08-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022) | Body Weight, Body Weight Changes, Insulin Resistance, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, diabetes mellitus, endocrine system disorder, glucose intolerance, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Active, not recruiting | Not applicable | 2025-08-29 | NCT05874635 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Signos Inc | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Signos | Palo Alto | United States | 2 |